Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report sent to investors on Friday. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently commented on CANF. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, December 31st.

View Our Latest Research Report on CANF

Can-Fite BioPharma Stock Up 0.6 %

Shares of CANF stock opened at $1.58 on Friday. The business has a 50-day moving average price of $1.79 and a two-hundred day moving average price of $2.31. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The firm has a market cap of $5.59 million, a P/E ratio of -0.88 and a beta of 1.36.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 21.00% of the stock is currently owned by institutional investors.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Featured Stories